@article {7505,
	title = {Clinical characteristics of patients with relapsed multiple myeloma q},
	journal = {Cancer Treatment Reviews},
	volume = {41},
	year = {2015},
	note = {Cited By :3Export Date: 21 February 2017},
	month = {2015},
	pages = {827 - 835},
	abstract = {Although survival outcomes have improved over the last decade for patients with multiple myeloma (MM), few patients remain free of disease and most inevitably relapse. Selecting a treatment for patients with relapsed MM is challenging given the number and diversity of regimens patients may have previously received, which can affect subsequent therapeutic choices. Importantly, a number of patient- and disease-related factors can also have an effect on treatment choice, treatment efficacy, and tolerability; thus, an understanding of the heterogeneity of patients in the setting of relapsed MM is important for appropriate treatment selection. Here, we review select patient and disease characteristics reported in key interventional and observational studies in relapsed MM (including age, sex, race, and the presence of high-risk disease, renal impairment, or peripheral neuropathy at baseline) to examine common and disparate features of patients with relapsed MM. As therapeutic regimens can have varying efficacy and/or tolerability in patients depending on these factors, we also provide treatment recommendations for patients with select baseline characteristics. {\textcopyright} 2015 The Authors.},
	keywords = {Immunomodulatory drug, multiple myeloma, proteasome inhibitor},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958860945\&doi=10.1016\%2fj.ctrv.2015.07.005\&partnerID=40\&md5=e17a362da157a327952035229f9d356e},
	author = {Dimopoulos, M.A. and Terpos, E. and Niesvizky, R. and Palumbo, A.}
}
